Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
Authors:
- Suzanne M M VerstappenSVSuzanne M M Verstappen
- Deborah P M SymmonsDSDeborah P M Symmons
- Kimme L HyrichKHKimme L Hyrich
- BSR Biologics Register BSRBR Control Centre ConsortiumBCBSR Biologics Register BSRBR Control Centre Consortium
Open Access
- 1 May 2011
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 70 (5) , 823-826
Abstract
Objective The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with anti-TNF in the BSRBR. Methods Patients were categorised according to anti-TNF exposure as follows: (1) exposure to anti-TNF and to methotrexate (MTX) and/or leflunomide (LEF) at conception (n=21 pregnancies); (2) exposure to anti-TNF at conception (n=50); (3) exposure to anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (control group; n=10). Results Eighty-eight live births in a total of 130 pregnancies were reported in patients who received anti-TNF before or during pregnancy. The rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with MTX/LEF 33% and without MTX/LEF 24%). This compared with 17% spontaneous abortions in those with prior exposure to anti-TNF and 10% spontaneous abortions in the control group. Ten terminations were performed. Conclusion Although the results to date have been promising, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy and, without further evidence, guidelines which suggest these drugs should be avoided at the time of conception cannot yet be changed.Keywords
This publication has 19 references indexed in Scilit:
- A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration DatabaseThe Journal of Rheumatology, 2009
- Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literatureJoint Bone Spine, 2009
- A prospective longitudinal population‐based study of clinical miscarriage in an urban Swedish populationBJOG: An International Journal of Obstetrics & Gynaecology, 2007
- Drug Insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactationNature Clinical Practice Rheumatology, 2007
- Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population registerArthritis & Rheumatism, 2006
- Biological drug use: US perspectives on indications and monitoringAnnals of the Rheumatic Diseases, 2005
- Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.2003
- Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practiceBMJ, 1997
- Incidence of Early Loss of PregnancyNew England Journal of Medicine, 1988